Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7)
- Target
- CEACAM7
- Molecular classification
- Cell adhesion molecule, Immunoglobulin superfamily, Carcinoembryonic antigen family
01
Overview
Carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7) is a cell surface glycoprotein belonging to the carcinoembryonic antigen family and the immunoglobulin superfamily. It is normally expressed on the apical surface of epithelial cells in the colon and rectum, where it mediates cell–cell adhesion and maintains epithelial differentiation. Expression of CEACAM7 is often downregulated in colorectal, rectal, and gastric cancers, and this loss correlates with tumor progression and poor prognosis, supporting a tumor suppressor role. Given its tumor-restricted expression pattern, CEACAM7 is being investigated as a potential prognostic biomarker and a therapeutic target, including in preclinical models of chimeric antigen receptor (CAR) T cell therapy directed against GI malignancies[1][2][6].
- Other names
- CEA cell adhesion molecule 7CGM2CEACarcinoembryonic antigen CGM2Carcinoembryonic antigen gene family member 2Cell adhesion molecule CEACAM7Carcinoembryonic antigen related cell adhesion molecule 7
02
Mechanism of action
Potential immunotherapeutic targeting (e.g., CAR T-cell mediated cytotoxicity)
03
Biological functions
Cell–cell adhesionMaintenance of epithelial differentiation
04
Disease associations
CancerGastrointestinal carcinomaColorectal cancerGastric carcinoma
05
Safety considerations
Limited data; potential challenges could include specificity for tumor tissue over normal tissue
06
Biomarkers
Prognostic biomarker in colorectal and rectal cancer (downregulation predictive of recurrence)Biomarker in gastric carcinoma (association with tumor progression)
Beyond the preview
Go deeper on Carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7).